Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.545 USD | -0.97% | -3.23% | -19.97% |
May. 15 | Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Transcript : Lumos Pharma, Inc., Q1 2024 Earnings Call, May 15, 2024 |
Financials (USD)
Sales 2024 * | 8.75M | Sales 2025 * | 8.66M | Capitalization | 20.86M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -40M | EV / Sales 2024 * | 2.38 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.41 x |
P/E ratio 2024 * |
-0.79
x | P/E ratio 2025 * |
-1.45
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.97% |
Latest transcript on Lumos Pharma, Inc.
1 day | -0.97% | ||
1 week | -3.23% | ||
Current month | -9.43% | ||
1 month | -9.11% | ||
3 months | -15.17% | ||
6 months | -15.73% | ||
Current year | -19.97% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 2.545 | -0.97% | 2 805 |
24-05-22 | 2.57 | +1.98% | 6,501 |
24-05-21 | 2.52 | -3.82% | 15,150 |
24-05-20 | 2.62 | +3.15% | 51,674 |
24-05-17 | 2.54 | -3.42% | 7,451 |
Delayed Quote Nasdaq, May 23, 2024 at 11:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.97% | 20.86M | |
+63.89% | 62.59B | |
-1.21% | 41.18B | |
+44.76% | 40.29B | |
-8.29% | 27.9B | |
+12.93% | 26.21B | |
-21.45% | 19.09B | |
+5.43% | 13.08B | |
+25.50% | 12.26B | |
+28.41% | 12.05B |
- Stock Market
- Equities
- LUMO Stock